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ABSTRACT
O
6-Methylguanine (O
6-meG) is a major mutagenic,
carcinogenic and cytotoxic DNA adduct produced
by various endogenous and exogenous methylating
agents. We report the results of transcription past a
site-specifically modified O
6-meG DNA template by
bacteriophage T7 RNA polymerase and human
RNA polymerase II. These data show that O
6-meG
partially blocks T7 RNA polymerase and human RNA
polymerase II elongation. In both cases, the
sequences of the truncated transcripts indicate
that both polymerases stop precisely at the
damaged site without nucleotide incorporation
opposite the lesion, while extensive misincorpora-
tion of uracil is observed in the full-length RNA.
For both polymerases, computer models suggest
that bypass occurs only when O
6-meG adopts an
anti conformation around its glycosidic bond, with
the methyl group in the proximal orientation; in con-
trast, blockage requires the methyl group to adopt a
distal conformation. Furthermore, the selection of
cytosine and uracil partners opposite O
6-meG is
rationalized with modeled hydrogen-bonding pat-
terns that agree with experimentally observed O
6-
meG:C and O
6-meG:U pairing schemes. Thus,
in vitro, O
6-meG contributes substantially to tran-
scriptional mutagenesis. In addition, the partial
blockage of RNA polymerase II suggests that tran-
scription-coupled DNA repair could play an auxiliary
role in the clearance of this lesion.
Methylating agents are among the array of chemicals that
damage the genome. They react with nucleophilic sites in
DNA, adding methyl groups to the purines, pyrimidines
and the phosphodiester backbone, resulting in modi-
ﬁcations that compromise the ﬁdelity and eﬃciency of
replication and transcription. These agents include exo-
genous compounds like N-methyl-N-nitrosourea, methyl
methane sulfonate and N-methyl-N0-nitro-nitrosoguani-
dine (1), along with endogenous biochemical agents like
S-adenosylmethionine (2) and metabolically nitrosated
amines and amides such as betaine and choline (3).
Nitrates and nitrites found in food and beverages can
also form methylating agents in cells (4). Hence, aberrant
DNA methylation is an unavoidable consequence of
metabolism and exposure to the surrounding environment
(5,6). Approximately 12 diﬀerent methylated DNA lesions
have been identiﬁed, with the relative amount of each
depending largely on the chemical nature of the reactive
alkylating species. The most frequent lesions occur at the
N7- or O
6-positions of guanine and the N3 position of
adenine (6,7).
O
6-Methylguanine (O
6-meG) (Figure 1) is a stable
DNA lesion formed by the reaction of methylating
agents, including the chemotherapeutic agents procarba-
zine and temozolomide, with guanine (8,9). O
6-MeG
is highly mutagenic since it often instructs DNA poly-
merases to incorporate thymine instead of cytosine, result-
ing in GC to AT transitions (10–12). The highly mutagenic
nature of O
6-meG oﬀers an explanation as to why methy-
lating agents that produce it are carcinogenic (13). But
O
6-meG can also block replication (14), inducing chromo-
somal aberrations, sister chromatid exchange and intra-
chromosomal homologous recombination (15–17).
O
6-MeG is repaired in a non-enzymatic, stoichiometric
fashion by the direct reversal protein O
6-methylguanine–
DNA methyltransferase (MGMT) (18). MGMT transfers
the methyl group from the lesion to a cysteine residue
within itself, rendering it incapable of continued repair;
hence, the number of O
6-meG lesions that can be cleared
from a cell’s genome is limited by the available MGMT
molecules, unless more of the protein is made. In fact,
variations in MGMT levels among cell types result in a
diﬀerential ability of organs and tissues to repair O
6-meG
via direct reversal, leading to the accumulation of O
6-meG
after MGMT is depleted (19,20).
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6-meG by several DNA polymerases
has been well studied (7,10,14,21–24); however, little
is known about its eﬀect on transcription elongation.
In Escherichia coli, RNA polymerase bypasses O
6-meG
with high eﬃciency, often misincorporating uracil oppo-
site the lesion. The resulting alterations to the transcripts
have been termed transcriptional mutagenesis (TM) (25).
Here, we examined transcriptional processing of O
6-meG
by bacteriophage T7 RNA polymerase (T7 RNAP) and
human RNA polymerase II (hRNAPII). These two poly-
merases diﬀer signiﬁcantly in the architecture of their
active sites and behave diﬀerently when facing DNA
lesions (26–28). It is shown here for the ﬁrst time that
O
6-meG poses a minimal hurdle to transcription by T7
RNAP, but it does impede hRNAPII transcription to a
signiﬁcant extent. Consistent with the previous study with
E. coli RNA polymerase (25), bypass of O
6-meG causes
signiﬁcant sequence alterations in the RNA transcripts,
with predominant misincorporation of uracil by both
polymerases. Computer modeling was utilized to provide
a structural explanation of the experimental results.
These models showed that the altered Watson–Crick
hydrogen-bonding edge of O
6-meG (Figure 1) underlies
the observed selectivity for uracil as well as cytosine incor-
poration during transcription past the lesion, with
hydrogen-bonding possibilities between O
6-meG and
uracil or cytosine that have been inferred in NMR solu-
tion studies (29–32) and observed in X-ray crystal struc-
tures of O
6-meG (22,33–36). In addition, the more
crowded active site region of hRNAPII explained the
greater blocking eﬀect of the lesion in this polymerase.
MATERIALS AND METHODS
Materials
Unless stated otherwise, all reagents, enzymes and biolog-
icals were purchased from Promega, Sigma-Aldrich,
New England Biolabs, Ambion or BioRad. DNA oligo-
mers were obtained from Sigma-Aldrich. Radioactive
materials were purchased from Perkin Elmer. All DNA
sequencing was done using the GeneAmp PCR System
Figure 1. Structures of the four possible conformations of O
6-meG. The glycosidic torsion angle ( ) deﬁned by the atoms O40–C10–N9–C4 is shown
in black and the torsion angle (k) deﬁned by the atoms N1–C6–O
6–C is displayed in red. The angle   is shown in both the anti (the six-membered
ring points away from the sugar) or syn (the six-membered ring is over the sugar) conformations, while the torsion angle (k) is in the distal (facing
N1–C6) or the proximal (facing away from N1–C6) orientation. These torsional possibilities give rise to four conformational combinations for the
lesion (A) anti,distal (B) anti,proximal (C) syn,distal and (D) syn,proximal O
6-meG. Guanine is shown as an inset to highlight the diﬀerent hydrogen-
bond donor/acceptor properties.
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Biosystems).
Transcription templateconstruction
DNA templates suitable for transcription by T7 RNAP
and hRNAPII were prepared as described in (26,27,37)
(Figure 2). In brief, the restriction endonuclease BbsI
was used to linearize the plasmid pCI-neo-G-less-T7,
which contained the two promoters needed for both
RNAPs (Supplementary Figure S1). A double-strand tail
was assembled by annealing three synthetic single-strand
DNA oligomers—an 11-mer and a 96-mer, to a comple-
mentary 90-mer containing a 50-biotin tag. The 11-mer
was either unmodiﬁed or modiﬁed with a site-speciﬁc
O
6-meG lesion, depending on whether a control or
adduct-modiﬁed template was being assembled, respec-
tively. DNA oligomers are shown in Table 1. T4 DNA
ligase was used to ligate the tail to the digested vector
for 16h at 168C. The product was precipitated using strep-
tavidin-linked beads, gel puriﬁed and tested for nicks as
described elsewhere (26,27,37).
Transcription reactions withbacteriophage
T7RNA polymerase
Transcription using T7 RNAP was performed as recom-
mended by the manufacturer Promega and as described
elsewhere (26,27). Brieﬂy, the transcription reactions con-
tained 20 units of T7 RNAP (a unit is deﬁned as the
amount of enzyme required to catalyze the incorporation
of 5nmol of CTP into acid-insoluble product in 60min at
378C in a total volume of 100ml), 25ng (0.033pmols)
of DNA template, 2.5mM each of ATP, GTP and UTP,
200mM[ a-
32P]CTP (50Ci/mmol), 100mM DTT and 10
units RNasin, 40mM Tris–HCl (pH 7.9at 258C), 10mM
NaCl, 6mM MgCl2 and 2mM spermidine in a ﬁnal
volume of 20ml. The molar concentrations provided are
the stock solution concentrations. The reaction was incub-
ated at 378C for 1h, the unincorporated nucleotides were
removed, and an equal volume of loading dye (80% for-
mamide, 5mM Tris–boric acid, 1mM EDTA, 0.1% bro-
mophenol blue and 0.1% xylene cyanol) was added to the
product, which was then resolved using denaturing
PAGE.
To test the eﬃciency of lesion bypass, a transcription
time course was performed. The reaction was initiated
as described earlier, and a radioactively labeled 108-base
DNA oligomer was added to the master mix to act as a
standard during PAGE. Aliquots were removed from the
reaction mix at time points 0, 1, 10, 20, 30, 40, 50 and
60min. Each aliquot was quenched by adding loading dye
and heating to 658C for 15min to ensure polymerase inac-
tivation. ImageQuant software (Molecular Dynamics) was
used to visualize and quantify the radiolabeled transcripts,
and for each time point, the RNA band intensity was
compared to the DNA standard intensity.
Transcription reactions with human RNA polymerase II
Multiple rounds of transcription reactions using
hRNAPII were performed as recommended by the man-
ufacturer Promega and as described in (26,27,37,38).
HeLa nuclear extract served as the source of the
hRNAPII machinery, and the presence of the CMV
enhancer/promoter on the DNA templates, which is spe-
ciﬁc for promoting transcription by RNAPII, ensured that
only hRNAPII complexes formed that could carry out
RNA elongation past the lesion (Promega and references
herein). Brieﬂy, transcription was carried out using 8 units
of HeLa nuclear extract (a unit is deﬁned as the amount
Figure 2. Site speciﬁcally modiﬁed DNA templates prepared for tran-
scriptional assays. The vector displayed in white is comprised of the
cloned T7 promoter and the CMV promoter/enhancer (black boxes).
The tail region is formed by annealing a 96-mer, a 90-mer and an 11-
mer (grey boxes). The position of the O
6-meG lesion is shown with a
triangle. The size of the template is 1140bp after digestion with EcoRV,
the last step during the puriﬁcation of the template which removes the
biotin tag from the tail end. The arrowheads indicate the +1 transcrip-
tion start site. The expected sizes of the RNA products obtained during
transcription by T7 RNAP and hRNAPII are shown below the
template.
Table 1. Sequence of DNA oligomers and primers used
Oligomer name DNA Sequence
96-mer
a 50-TTGCGGTAGCGATGGGTGCTGTACTCAGGTGTGG
AATCAACCCACAGCTGACAGGGCAGGTCTTGGCCAG
TTGGGATATCCAAAACATCTTGTTGA-30
90-mer
a 50-TTTTTTTTTTCAACAAGATGTTTTGGATATCCCAA
CTGGCCAAGACCTGCCCTGTCAGCTGTGGGTTGATTCC
ACACCTGAGTACAGCAC-30
11-mer
a 50-CCATCGCTACC-30
49L
b 50-GCTTCCTCATCCTTCTCCATCTCTCTGTGCAGCTG
TGGGTTGATTCACG
24F
c 50-AACGCAGTCAGTGCTTCTGACACA-30
25R
c 50-GAGAGATGGAGAAGGATGAGGAAGC -30
22R trunc 50-TACAGTGCTCGCATACGCTCAA-30
24 chimera 50-UUUUGAGCGTATGCGAGCACTGTAidt-30
aThe 96-mer, 90-mer and the 11-mer were annealed to make the tail of
the DNA templates. The bold underscored G in the 11-mer represents
either the undamaged guanine or the damaged O
6-meG.
b49L is the primer used in the reverse transcription of the full-length
RNA obtained from transcription of T7 RNAP past the DNA
templates.
c24F and 25R are the forward and reverse PCR primers.
22R: The reverse transcription primer used in the ligation mediated
reverse transcription. It is complementary to the chimera, which was
ligated to the RNA prior to reverse transcription.
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nucleotides into a 363-nt runoﬀ transcript ‘generated
from the CMV immediate early promoter fragment’ per
hour at 308C), 100ng (0.15pmols) DNA template,
10units of RNase inhibitor, 3mM MgCl2, 10mM each
of ATP, GTP and UTP, 0.4mM CTP, 1ml[ a-
32P]CTP
(25Ci/mmol), 20mM HEPES (pH 7.9at 258C), 100mM
KCl, 0.2mM EDTA, 0.5mM DTT, 20% glycerol in a
ﬁnal volume of 25ml (Molar concentrations provided are
the stock solution concentrations). The reaction was incu-
bated at 308C for 60min, and then quenched using a stop
solution [0.3M Tris–HCl (pH 7.4 at 258C), 0.3M sodium
acetate, 0.5% SDS, 2mM EDTA and 3mg/ml tRNA] pro-
vided by the manufacturer (Promega). The resulting RNA
was puriﬁed by phenol:chloroform extraction and
resolved using denaturing 7% PAGE.
For a single round of transcription, GTP was omitted
from the NTP mix, and the polymerase complex was
allowed to transcribe up to the point at which the ﬁrst
GTP was required. After 10min, heparin was added to
bind all free hRNAPII. Finally, the addition of 100mM
GTP allowed transcription to continue, and after an addi-
tional 40min, the reaction was quenched. The resulting
RNA was puriﬁed by phenol:chloroform extraction and
resolved using denaturing 7% PAGE.
To test the eﬃciency of lesion bypass, a transcription
time course was performed. In order to prevent repair of
O
6-meG, HeLa nuclear extracts were pre-incubated with
0.5 mM O
6-benzylguanine (BZG), a potent inhibitor of the
MGMT that repairs O
6-meG (39). A loading standard 175
bases in length was added to the reaction mix, and the
transcription reaction was initiated by the addition of
the DNA template as described earlier. Aliquots were
removed from the reaction mix, and quenched in stop
solution at time points 0, 1, 5, 10, 20, 30, 40 and 60min.
The resulting RNA was puriﬁed and resolved on 7%
PAGE. ImageQuant software (Molecular Dynamics) was
used to visualize and quantify the radiolabeled transcripts.
At each time point, RNA band intensity was used to
determine the percentage of each RNA species present.
RNA sequencing
To sequence full-length transcripts, transcription reactions
were performed without radioactive CTP but with all four
non-radioactive nucleotides, each at a concentration
of 500mM for T7 RNAP and 400mM for hRNAPII.
Transcription reactions were followed by digestion with
RNase-free DNase at 378C for 30min to destroy any
residual DNA template. The resulting RNA was puriﬁed
and sequenced using the reverse transcriptase polymerase
chain reaction (RT–PCR). In brief, for the reverse tran-
scriptase reaction, 20 pmol of primers were annealed to
the RNA template, ImProm II (Promega) was used as a
source of reverse transcriptase, and the reaction was per-
formed following the manufacturer’s protocol. Residual
RNA was digested with RNase, and the RNase was sub-
sequently heat inactivated. Excess primers and small RNA
fragments were eliminated by using Microcon Centrifugal
Filter Columns. Finally, PCR was performed with the
forward and reverse primers 24F and 25R (Table 1).
To sequence the truncated transcripts, 1mM of a chi-
meric RNA–DNA oligomer, 24 chimera (Table 1), was
ligated to the 30-ends of the transcripts using T4 RNA
ligase and DMSO (40). The chimeric RNA–DNA oligo-
mer contains four ribonucleotides at its 50-end to facili-
tate ligation to the transcripts using RNA ligase; the
other bases of the oligomer are deoxyribonucleotides
that make the chimeric oligomer resistant to degradation.
The reverse transcriptase primer 22RTrunc was annealed
to the tail, and RT–PCR was subsequently performed.
This approach selected all RNA, both the full-length
and the truncated transcripts to which the chimeric oligo-
mer was ligated.
For both full-length and truncated RNA, the RT–PCR
products were cloned and sequenced. The RT–PCR pro-
ducts were puriﬁed using a 1.2% non-denaturing agarose
matrix and subsequently inserted into the pDrive vector
(Promega) speciﬁcally designed for cloning PCR products.
The cloned PCR products were used to transform Qiagen
EZ competent cells grown on agar plates containing kana-
mycin and IPTG. Only white colonies, indicating the
insertion of the PCR product in the vector, were selected
and grown overnight in Luria broth supplemented with
ampicillin. Plasmids were extracted from the cells using
the QIAprep Spin Miniprep Kit (Qiagen) and were
then sequenced. For each polymerase, 100 clones were
sequenced for full-length products and 50 clones
were sequenced for the truncated products (26,27).
Molecular modeling ofO
6-meGin T7RNAP
To model the O
6-meG adduct in the active site of T7
RNAP, four available X-ray crystal structures of the pro-
tein were used. The crystal structures represent four
phases of one cycle of nucleotide addition during the elon-
gation phase of transcription: the pre-insertion substrate
complex, the insertion substrate complex, the pre-translo-
cation product complex and the post-translocation com-
plex with PDB codes 1S0V (41), 1S76 (42), 1S77 (42) and
1MSW (43), respectively. These structures are shown in
Supplementary Figure S2. In each phase, the protein
was crystallized in a ternary complex with a DNA
duplex of approximately 30 bases, a 9 base DNA:RNA
hybrid, and an incoming ribonucleotide, except for the
post-translocation phase. Sequences of the template/non-
template DNA and the RNA transcript were re-modeled
to match the sequences used in the study reported here
(Figure 3).
The structure of the damaged O
6-meG base was
obtained from a crystal structure of the lesion paired
with a cytosine [PDB code 1D24 (33)]. The unmodiﬁed
guanine at position i+1 or i+2 (only in the post-translo-
cation complex) of the template strand was replaced by
this O
6-meG structure (Figure 3). The subsequent search
for optimal structures employed the following procedure.
The glycosidic torsion angle of the lesion was retained in
the original anti conformation present in the crystal (  =
2528) (Figure 1A and B). The base of the crystal NTP was
replaced by cytosine or uracil while retaining the original
anti conformation of the glycosidic torsion angle
( =1968). The torsion angle (k) (Figure 1) governing
6462 Nucleic Acids Research, 2008, Vol. 36, No. 20the methyl group conformation of the adduct was then
rotated utilizing the INSIGHTII (Accelrys) utility bump-
check in a search for structures with minimal collisions.
This torsion angle has been observed in crystal structures
to adopt two conformational ranges termed distal
and proximal with (k) values in the range of 0–768 and
159–2088, respectively (22,33–36,44). However, to accom-
modate the incoming pyrimidines, only the proximal con-
formation for (k), ranging from 1828 to 1918, provided
structures without clashes. The structure with k=1838
was used for further study, as this value fell in the
middle of the range of proximal k-values (159–2088) pre-
viously observed in crystal structures of O
6-meG
(22,34–36,44). Subsequently, the slight, close contacts
remaining (<2A ˚ ) were relieved by rotation of the side
chain of Arg-632, namely around the Ca–Cb,C b–Cg and
Cg–Cd bonds. Finally, additional adjustments were made
to the torsion angle ( ) of the NTP (<158) in order to
locate structures with optimal hydrogen bonds between
O
6-meG and the incoming NTP.
In the case of an incoming ATP, the original anti con-
formation of O
6-meG exhibited severe collisions with the
ribonucleotide. To relieve the clashes observed in the
model and explain the insertion of adenine in the growing
RNA as identiﬁed by the biochemical results, the torsion
angle ( )o fO
6-meG was continuously rotated to ﬁnd the
range of minimal collision, which was in the syn domain.
As with the incoming pyrimidines, slight close contacts
(<2A ˚ ) were relieved by rotation of the side chain of the
same Arg-632, namely around the Cb–Cg,C g–Cd and
Cd–Ne bonds. When a collision-free range was obtained,
the torsion angle ( ) of the lesion was further rotated
slightly (<38) to locate a conformation with optimal
hydrogen-bonding possibilities between the incoming
ATP and O
6-meG. No NTP was present opposite the
base at i+2 in the post-translocation complex. The hydro-
gen-bonding criteria in the insertion complex were in the
following observed ranges (22,45–50): (1) donor to accep-
tor atom distance of 2.5A ˚ < X–A< 3.9A ˚ ; (2) hydrogen to
acceptor atom distance of 1.5A ˚ < H–A < 2.9A ˚ ; and (3)
angle   deﬁned by the donor–hydrogen–acceptor atoms
(X–H–A) >908. Full details for the torsion angles and
the resulting hydrogen bonds in all the modeled structures
are provided in Tables S1 and S2, respectively.
Molecular modeling of O
6-meG inyeast RNA polymerase II
Crystal structures for the hRNAPII are not available at
this writing. However, crystal structures for yeast
S. cerevisiae RNAPII (yRNAPII) shares 53% sequence
identity with the human polymerase, and the conserved
residues are distributed over the entire structure (51). In
addition, cryo-electron microscopy with image reconstruc-
tion and variance analysis of the hRNAPII together with
homology modeling of the human enzyme based on the
yRNAPII show that the human and the yeast enzymes’
cores that contain the active sites are structurally indistin-
guishable (52). This makes the yeast polymerase a good
model for the human enzyme. The X-ray crystal structure
of S. cerevisiae RNAPII, PDB code 2NVZ (53), was in a
ternary complex form with a 29-base DNA template
strand, a 10-base RNA transcript and a 14-base non-
template DNA strand complementary to the template
strand downstream of the RNA. This structure was used
as the starting model for yRNAPII containing the
O
6-meG lesion in its active site. The modeling procedures
employed for yRNAPII were very similar to the proce-
dures described earlier for T7 RNAP. First, the unda-
maged templating base present in the crystal was
replaced by the lesion while retaining its original glycosi-
dic torsion angle ( =1878), placing the damaged guanine
in an anti conformation. Then, the torsion angle k was
continuously rotated to ﬁnd a collision-free range for the
methyl group (k=200–2508). The original crystal con-
tained a uracil as an incoming ribonucleotide. Therefore,
to explain the incorporation of uracil opposite the lesion
as shown in the experimental results, the possibility of
hydrogen bonding between O
6-meG and uracil was eval-
uated. Hydrogen-bonding requirements followed the cri-
teria speciﬁed earlier for the T7 RNAP models. Next, the
incoming ribonucleotide was remodeled to a cytosine, to
interpret its observed incorporation in the RNA; again the
glycosidic torsion angle was retained as in the crystal
( =2208), and ﬁnally, hydrogen-bonding possibilities
with O
6-meG were investigated. All modeling was carried
outwiththeBiopolymermoduleofINSIGHTII(Accelrys),
and all images were generated using the PYMOL program.
RESULTS
DNA templates suitable fortranscription were synthesized
andconfirmed to be free of nicks
DNA templates were constructed with a site-speciﬁc
O
6-meG on the transcribed strand. The lesion was posi-
tioned downstream from the CMV enhancer/promoter
and the T7 RNAP promoter to allow for comparisons
between the two RNAPs transcribing past O
6-meG
(Figure 2). Unmodiﬁed templates acted as control DNA.
To test for the presence of nicks in the ligated products,
the constructed templates were digested with I-PpoI,
an endonuclease that cuts with high speciﬁcity at a 15-
bp recognition sequence. The fragments were radiolabeled
Figure 3. Sequences employed in the experimental and modeling studies
in T7 RNAP and yRNAPII complexes. The insertion position i+1
occupied by the template nucleotide to be transcribed, G or O
6-meG
is shown in cyan. The pre-insertion position i+2 occupied by the next
to be transcribed nucleotide is in grey. The ribonucleotide previously
incorporated at the 30-end of the RNA is designated R1 and shown in
green. The rNTP to be inserted opposite the lesion is called Incomer
and colored red and the non-template DNA strand is colored in purple.
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ligation is complete, the resulting DNA fragments should
be 187, 191 and 953 bases in length. In contrast, incom-
plete ligation that results in the presence of nicks in the
template would result in fragments 73, 77, 110 or 118
bases in length. The absence of the shorter bands indicates
that ligation was indeed eﬃcient, and the templates for
transcription were free of nicks (Supplementary
Figure S3).
O
6-MeG minimally blocks T7RNA polymerase elongation
Transcription of the unmodiﬁed DNA with T7 RNAP
produced only full-length RNA 340 bases in length. In
contrast, transcription of the modiﬁed DNA template pri-
marily produced full-length transcripts 340 bases in
length, with some truncated RNA of approximately 274
bases (Figure 4A). The percentage of full-length RNA
averaged from nine separate reactions was 95 1%. The
one percent value represents the standard deviation from
the mean. The shorter transcripts coincided with the posi-
tion of O
6-meG on the template strand, indicating that
this lesion impedes elongating T7 RNAP. The shorter
RNA molecules observed between 274 and 340 bases
were also obtained with the unmodiﬁed templates;
hence, inherent pause sites on the DNA likely cause
their formation, not the damaged base.
Experiments were carried out to examine T7 RNAP
lesion bypass eﬃciency over time. Aliquots were removed
from the reaction mix at diﬀerent times as described in the
Materials and Methods section. For each time point, the
RNA band intensity was compared to a DNA standard
of 108 bases in length. The experiment was performed in
triplicate, and in each case, the undamaged templates pro-
duced increasing amounts of full-length RNA over time
(Figure 4B, lanes 1 through 8), while the O
6-meG-
damaged templates produced mainly full-length tran-
scripts ( 95%), with a small amount of truncated RNA
( 5%) (Figure 4B, lanes 9 through 16). The results suggest
that rapid RNA synthesis is mildly obstructed by O
6-meG.
O
6-MeGpartially blocks human RNA polymeraseII
transcription
HeLa nuclear extract was used as the source of hRNAPII
machinery. The presence of the CMV enhancer/promoter
on the DNA templates supports hRNAPII transcription
initiation alone, as described in the manufacturer’s
Figure 4. Eﬀect of O
6-meG modiﬁed-DNA on transcription by T7 RNAP. (A) T7 RNAP transcription of the unmodiﬁed DNA resulted in full-
length RNA (FL) approximately 340 bases in length (lane 1) while the modiﬁed template resulted in a mixture of two RNA species approximately
274 and 340 bases in length (lane 2). A 50bp DNA step ladder is labeled M. (B) Time course of transcription with T7 RNAP past the undamaged
DNA (lanes 1 through 8) and the O
6-meG template (lanes 9 through 16). Aliquots were removed every 10min to measure the extent of lesion
blockage or bypass over time. Fragments were compared to a DNA standard of 108 bases in length used to minimize loading errors. The increased
intensity across lanes indicates an increased amount of RNA over time. Transcription past the damaged templates shows that the lesion poses a
minor obstruction to the rapid RNA synthesis. (C) The graph illustrates the percent of full-length RNA. It indicates that the amount of full-length
RNA remains the same over time (95%) and that the lesion causes the production of  5% of truncated RNA at any time point.
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single and multiple rounds of transcription were carried
out on undamaged and damaged templates. For single
rounds of transcription, a G-less cassette was utilized to
synchronize the reaction so that a template could be tran-
scribed only once by a single RNA polymerase (54). For
multiple rounds of transcription, a template could be tran-
scribed multiple times by several polymerase complexes.
After 60min, both single and multiple rounds of transcrip-
tion using the unmodiﬁed control resulted in the forma-
tion of full-length transcripts 383 bases in length, with no
truncated transcripts occurring in the vicinity of the
O
6-meG (Figure 5A, lane 1). However, transcription
using the damaged template produced truncated and
full-length RNA of 316 and 383 bases in length, respec-
tively. Single round of transcription produced 64 6% of
full-length RNA, while multiple rounds of transcription
produced 74 2% of full-length RNA. The data obtained
represent the average of 10 separate transcription experi-
ments, with standard deviations from the mean given.
As with T7RNAP, time course experiments were carried
out to examine hRNAPII lesion bypass eﬃciency over
time. We carried out these transcription reactions in the
presence of 0.5mM BZG to ensure that repair of O
6-meG
does not occur. The time course shows that undamaged
templates only produce full-length RNA over time
(Figure 5B, lanes 1 through 8), while templates containing
O
6-meG produced a constant ratio of full-length ( 60%)
and truncated RNA ( 40%) at each time point after the
ﬁrst 10min (Figure 5B, lanes 10 through 17). These results
suggest that RNA synthesis is partially obstructed by O
6-
meG and that repair of the damaged templates is unlikely
to occur during the course of the performed transcription
reaction as performed here.
Note that the addition of BZG to the HeLa nuclear
extracts resulted in a decrease in the amount of full-
length RNA, from 74% to  58% at 60min, indicating
that the extracts may have some MGMT activity which
is thwarted in the presence of BZG, eliminating repair of
the lesion. Note that nucleotide excision repair (NER)
does not recognize O
6-meG in human cell extracts (55),
indicating that this pathway is not responsible for the
repair of the lesion. Furthermore, mismatch repair does
not remove O
6-meG but replaces the mismatched thymine
on the opposite strand (56); hence, this pathway is also not
responsible for the clearance of this lesion in the extracts.
T7RNAP and hRNAPII generateextensive base
misincorporation oppositeO
6-meG in full-length RNA
RT–PCR was used to sequence the full-length and trun-
cated RNA following transcription of DNA templates
that contain O
6-meG. The resulting PCR products con-
sisted of a heterogeneous population of DNA, necessitat-
ing subcloning to analyze individual RT-PCR products.
For full-length transcripts resulting from T7 RNAP tran-
scription past the O
6-meG templates, the polymerase
Figure 5. Eﬀect of O
6-meG modiﬁed-DNA on transcription by hRNAPII. (A) Single and multiple rounds of transcription using HeLa nuclear
extracts. Undamaged templates generated full-length (FL) transcripts of approximately 383 bases in length (lanes 1 and 2) while O
6-meG-damaged
templates produced two RNA species of 383 and 316 bases in length (lanes 3 and 4). A 50bp DNA step ladder is shown (M). (B) Time course of
transcription with hRNAPII past the undamaged DNA (lanes 1 through 8) and the O
6-meG template (lanes 10 through 17). Aliquots were removed at
the time points indicated on the ﬁgure to measure the extent of lesion blockage or bypass over time. Fragments were compared to a DNA standard of 175
bases in length used to minimize loading errors. Transcription past the damaged templates shows that the lesion partially obstructs RNA synthesis (only
producing  60% of full-length RNA at time points 20min through 60min). The graph illustrates the % of full-length and truncated RNA over time
(x-axis). It indicates that the amount of full-length and truncated RNA remain almost constant after the ﬁrst ten minutes of the transcription reaction.
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each) and adenine to a very small extent (6%) (Table 2).
Undamaged templates produced only full-length tran-
scripts having the correct base sequence (data not
shown). In the case of full-length RNA obtained for
hRNAPII bypass of O
6-meG, cytosine and uracil were
exclusively incorporated opposite the lesion with a 3:1
ratio. Misincorporation of adenine was not observed in
full-length RNA generated by hRNAPII (Table 2).
For the truncated transcripts, T7 RNAP often stalled
exactly at the site of the lesion and did not permit nucleo-
tide incorporation opposite it. In some cases, T7 RNAP
was able to misincorporate either one adenine or a cyto-
sine followed by two non-template instructed adenines
before terminating transcription (Table 3). In contrast,
hRNAPII typically stopped at the site of O
6-meG, but
without nucleotide incorporation opposite the lesion.
Additionally, hRNAPII misincorporated cytosine oppo-
site the base immediately preceding O
6-meG, which was
cytosine, and then stopped (Table 3).
Modelingsuggests hydrogen-bonding possibilities
that explainobserved nucleotide selectivity
Bacteriophage T7 RNAP. Molecular modeling was
employed to provide a structural rationale for the experi-
mentally observed ﬁndings: full-length RNA exhibited sig-
niﬁcant base misincorporation events opposite the lesion
with base selectivity C=U >> A, and shorter transcripts
were truncated one residue before the lesion. Two glyco-
sidic bond conformations ( ) for the O
6-meG nucleoside
were investigated, namely anti and syn (Figure 1). Our
models showed that when the O
6-meG nucleoside was in
the anti conformation, it allowed the insertion of pyrimi-
dine NTPs with no steric collisions, provided that the
methyl group adopted the proximal conformation relative
to the N1 atom (Figure 1B). This conformation avoided
collision with incoming pyrimidines and allowed base
pairing to occur. For CTP, two hydrogen-bonding inter-
actions were identiﬁed, one between N4 of cytosine and O
6
of O
6-meG and another between O
2 of cytosine and N
2 of
O
6-meG. In case of an N3-protonated cytosine, an addi-
tional hydrogen bond could occur with the N1 of O
6-meG.
A protonated cytosine would allow a Watson–Crick-like
pairing between the lesion and the incoming NTP similar
to what was identiﬁed crystallographically (29,33,36)
(Figure 6B). In the case of UTP, two hydrogen bonds
were found possible, one between N3 of uridine and N1
of O
6-meG, and the second between O
2 of uridine and N
2
of O
6-meG. This O
6-meG:U pair is in a ‘Watson–Crick
isosteric’ conformation (36), also termed ‘pseudoWatson–
Crick’ (22), and was observed crystallographically
(33,34,36) (Figure 6C).
In order to accommodate an incoming adenine, the
O
6-meG nucleoside had to adopt the syn conformation
around its glycosidic bond ( ) to avoid overlap with the
six-membered ring of the adenine. In addition, the methyl
group had to be oriented in the distal conformation
(Figure 1C). In this conformation, the methyl could
be housed, without collision, in the polymerase active
site pocket on the major groove side of the damaged gua-
nine, allowing the incorporation of adenine opposite it.
Interestingly, this syn conformation was stabilized
by one hydrogen bond between the O
6 of O
6-meG
and a protein side chain of Gln-649 (Figure 7 and
Supplementary Table S2B). The syn ( ) distal (k) confor-
mation of the lesion allowed for one hydrogen-bonding
interaction between the N
6 of the incoming ATP and the
O
6 of the O
6-meG. For the case of an N1-protonated
adenine, as observed in crystal structures (57,58), an addi-
tional hydrogen bond could form between the N1 hydro-
gen of the ATP with the N7 of the lesion (Figure 6D).
These hydrogen-bonding possibilities oﬀer an explana-
tion for the incorporation of cytosine and the misincor-
poration of uracil and adenine in the RNA opposite
O
6-meG during transcription elongation by T7 RNAP:
equal insertion of cytosine and uracil is consistent with
their equivalent hydrogen-bonding possibilities with
O
6-meG, while the much smaller selection for adenine is
explained by the requirement for the abnormal and less-
prevalent syn conformation of the templating lesion in
order to allow hydrogen bonding with the incoming
ATP (Figures 6 and 8). We have given detailed results
for the substrate insertion complex, but the models were
essentially identical for the pre-translocation product
complex and quite similar in the post-translocation and
the substrate pre-insertion complexes. Detailed results of
the torsion angles and the hydrogen-bonding partners are
given in Tables S1 and S2.
Yeast RNAPII (yRNAPII). As detailed in the Materials
and Methods section, current evidence indicates that the
active site regions of yeast and human RNA polymerase II
are in fact nearly identical (51,52). This makes the yeast
polymerase a suitable model for the human enzyme.
Hence, molecular modeling was employed to explain the
Table 3. Bases incorporated opposite O
6-meG in the truncated RNA
during transcription with T7 RNAP and hRNAPII
a
Sequence RNA
length
(bases)
Percentage
Expected RNA
sequence
...UCUUGCGGUAGCGAUGG
Sequence obtained
with T7 RNAP
...UCUUGCGGUAG 272 25
...UCUUGCGGUAGA 273 25
...UCUUGCGGUAGCAA 275 50
Sequence obtained
with hRNAPII
...UCUUGCGGUAG 272 80
...UCUUGCGGUAC 20
aBold, underscored bases represent misincorporated bases after the
lesion.
Table 2. Bases incorporated opposite O
6-meG in the full-length RNA
during transcription with T7 RNAP and hRNAPII
% rNTP C U A
RNAP
T7 RNAP 47 47 6
hRNAPII 75 25 –
6466 Nucleic Acids Research, 2008, Vol. 36, No. 20observed incorporation of C and to lesser extent U oppo-
site the lesion in the full-length RNA using yRNAPII. No
adenine incorporation was observed. In the case of the
truncated transcripts, nucleotide incorporation did not
occur opposite the O
6-meG lesion. To explain the
observed bypass events, the models had the glycosidic
bond ( ) for the O
6-meG nucleoside in the anti conforma-
tion and there was a range in k around the O
6–C6 bond
which was collision free (k=200–2508), similar to the T7
RNAP bypass models. In this domain, the lesion was in an
anti, proximal orientation (Figure 1B). We term this
orientation the bypass conformation because it is compa-
tible with nucleotide incorporation into the RNA. The
anti, proximal orientation of the O
6-meG allowed for the
formation of two hydrogen bonds with each of the incom-
ing pyrimidines. For CTP, the hydrogen bonds involved
the N
4 of cytosine with O
6 of O
6-meG, and the O
2 of
cytosine with N
2 of O
6-meG. Again, in the case of an
N3-protonated cytosine, an additional hydrogen bond
could form with the N1 of O
6-meG. For UTP, the two
hydrogen bonds involved the N3 of uridine with N1 of O
6-
meG and the O
2 of uridine with N2 of O
6-meG. These
Figure 6. Hydrogen-bonding interactions between (A) a G:C pair,
O
6-meG and (B) cytosine, (C) uridine and (D) adenine, respectively
(see text). (A) G:C pair; G(O
6):C(N
4), G(N1):C(N3), and G(N
2):
C(O
2), (B) anti,proximal O
6-meG:C pair; O
6-meG(O
6):C(N
4) and
O
6-meG(N
2): C(O
2), (C) anti,proximal O
6-meG:U pair; O
6-meG(N1):
U(N3) and O
6-meG(N
2):U(O
2) and (D) syn, distal O
6-meG:A pair;
O
6-meG(O
6): A(N
6). Hydrogen bonds involving potential protonation
sites, O
6-meG(N1):C(N3
+) and O
6-meG(N7):A(N1
+) are shown in
pink. The methyl group carbon is colored in green. Color code is the
same as in Figure 3. Details of the potential hydrogen-bonding partners
are described in Supplementary Table S2.
Figure 7. H-bond interaction between O
6-meG and the T7 RNAP resi-
due, Gln-649. The O
6-meG in the syn conformation is stabilized by one
hydrogen bond between the O
6 of O
6-meG and the Ne of Gln-649. The
hydrogen bond is shown as a dotted black line. Hydrogens of the back-
bone were removed for clarity. Color code is the same as in Figures 3
and 6.
Figure 8. View of the O
6-meG lesion pairing with cytosine (gray), uracil
(cyan) and adenine (violet) inside the active site of T7 RNAP. The
backbone of the protein is rendered in transparent cartoons, superim-
posed on the three pairs and colored using the same code as the
DNA:RNA pair shown in the ﬁgure. The methyl group of the lesion
is shown as a red sphere. For lesion pairing with cytosine or uracil, the
O
6-meG:C and O
6-meG:U pairs superimpose completely and mimic a
normal Watson–Crick base pair. With the O
6-meG:A pair, the O
6-meG
must adopt the less-prevalent syn conformation for collision-free place-
ment of the incoming rATP.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6467hydrogen-bonding schemes, which are detailed in Figure 6
and Supplementary Table S3, are similar to what was
obtained for T7 RNAP, and explain the incorporation
of uracil and cytosine in the growing RNA.
When the methyl group was outside the allowed k
range, it collided with either the incoming ribonucleotide
or neighboring protein residues, namely Thr-827, Ala-828,
Val-829 of the bridge helix. These collisions could not be
alleviated by minimal rotation of the side chains of the
helix, because slight rotations of the bridge helix residues
cause severe distortions to the yRNAPII structure (53).
This conformational range (k6¼200–2508), termed the
blocking structure, provides a model to explain the halting
of the polymerase opposite O
6-meG.
The modeling studies showed that ATP could not
be accommodated with the O
6-meG in the anti glycosidic
bond conformation due to collisions between the lesion
and the large purine. While, it was possible to obtain a
collision-free structure containing ATP, this structure was
otherwise unfavorable. The lesion could only be placed in
a narrow region of the syn domain ( =238–2438)
with k in the distal conformation (k=172–2388)
(Figure 1C). This structure had two hydrogen bonds
between the Hoogsteen edge of the O
6-meG and the A
[N
6(A):O
6(meG) and N1
+(A):N7(meG)], but it contained
an unfavorable repulsive interaction between the O
6 and
an oxygen of Ala-828 of subunit 1 of yRNAPII, with close
distance of  2.6A ˚ (Supplementary Figure S4). This repul-
sive interaction together with the small region of confor-
mational space in   that is permissible sterically would
make this structure unlikely to occur. Thus, the observed
failure to incorporate adenine is reasonable on the basis of
these models.
DISCUSSION
Gene expression is a tightly regulated process that requires
RNA polymerase to read a transcription unit when direc-
ted. To achieve this, an unperturbed, processive elonga-
tion complex centered around an RNA polymerase is
essential. However, transcription is often obstructed by
pausing sequences, protein roadblocks (59) or DNA
damage (60). More speciﬁcally, unrepaired damage pres-
ent on the transcribed strand of a gene can either block an
elongating RNA polymerase or lead to bypass with
nucleotide insertion opposite or near the site of the
damage (60). While arrest of transcription is believed to
trigger TCR, lesion bypass can induce TM (25).
Here we report that, in the current sequence context,
O
6-meG partially blocks transcription elongation of
both T7 RNAP and hRNAPII, albeit to diﬀerent extents
(Figures 4 and 5); the lesion poses a more signiﬁcant block
to hRNAPII. Although, there have been contradictory
reports on the preferential repair of O
6-meG from the
transcribed strand of a gene (61,62), our results indicate
that partial polymerase blockage by O
6-meG raises the
possibility that this lesion might invoke TCR (63).
Hence, the blocked polymerase could provide an addi-
tional means for cells to identify O
6-meG, not recognized
by the MGMT protein. This possibility needs to be inves-
tigated further.
In addition, we show the contribution of O
6-meG to
TM in vitro. T7 RNAP bypasses the lesion eﬃciently but
with low ﬁdelity, resulting in a high frequency of nucleo-
tide misinsertion opposite the lesion with selectivity C=
U=47% >> A=6%. Similarly, hRNAPII bypasses O
6-
meG with misincorporation of uracil in 25% of the full-
length RNA. During gene expression and mRNA transla-
tion, each protein-encoding mRNA is translated about 40
times on average; therefore, an error in the primary code
of the RNA, such as produced by O
6-meG, can lead to a
burst eﬀect of ﬂawed proteins (64). In this connection, it is
interesting that the incorporation of uracil was evidenced
during a transcriptional assay past O
6-meG in human cells
(Burns,J.A. Dreij,K. and Scicchitano,D.A. unpublished
data). Hence, our work adds O
6-meG to the pool of smal-
ler DNA lesions that partially block transcription and
may induce TM; others include the oxidative lesions 8-
oxoguanine (65,66), thymine glycols (67) and cisplatin
1,2-intrastrand d(GpG) crosslinks (68).
Sequences of the truncated RNAs showed that when T7
RNAP and hRNAPII stopped at the lesion, nucleotide
incorporation opposite O
6-meG was not permitted
(Table 3). Modeling indicated that in both polymerases
transcription blockage would ensue if the lesion adopts
an anti, distal orientation, shown in Figure 1A. In the
distal orientation, the methyl group is in close proximity
to the incoming ribonucleotide, producing steric collisions
that thwart incorporation and elongation. Moreover, the
greater blockage observed with hRNAPII could be attrib-
uted to the occurrence of a distal conformation of the
methyl group which highly crowds the incoming NTP in
the more conﬁned hRNAPII. Interestingly, two additional
truncated RNAs were obtained during transcription by T7
RNAP with either an additional adenine or a cytosine
followed by two non-template instructed adenines
(Table 3). These two truncated RNA species were also
observed in other studies where T7 RNAP stalled at
damaged guanines namely 1,N
2-ethenogunaine (1,N
2-eG)
(26) and 5-guanidino-4-nitroimidazole (NI) (27). This
behavior may therefore be inherent to the stalled T7
RNAP and independent of the lesion. It has been sug-
gested that stalled RNA polymerases tend to add one or
two bases at the 30-end of transcripts (69) further support-
ing our observation.
The bypass events observed with O
6-meG can be
explained on the basis of the altered hydrogen-bonding
possibilities of O
6-meG compared to guanine (Figure 1).
Speciﬁcally, the hydrogen-bond acceptor atom N1 of gua-
nine becomes a hydrogen-bond donor in O
6-meG. With
the lesion in an anti-proximal conformation our models
showed that, in both polymerases, there were no collisions
with the incoming UTP or CTP. We readily modeled
a pseudo Watson–Crick base pair with uracil (22) and
a Watson–Crick-like pair with cytosine (36). Each pair
allowed two hydrogen bonds between the lesion and the
incoming nucleotide (Figure 6B and C). A protonated
cytosine allowed three hydrogen bonds to form
with an alignment that is very near Watson–Crick.
These pairing schemes were feasible in both T7 RNAP
6468 Nucleic Acids Research, 2008, Vol. 36, No. 20and yRNAPII, and a number of crystal structures (22,33–
36) and NMR solution studies (29–32) have revealed the
base-pairing possibilities for O
6-meG present in our
models. While a wobble interaction with cytosine
[N
4(C):N1(O
6-meG) and N3(C):N
2(O
6-meG)] was also
seen in crystal structures (70) and inferred by NMR solu-
tion studies (32), this scheme requires rearrangement in
the DNA backbone which could be energetically costly.
The preference for cytosine over uracil incorporation
opposite O
6-meG in yRNAPII probably stems from the
more conﬁning active site region of yRNAPII, which
likely selects more stringently for a hydrogen-
bonding scheme closest to Watson–Crick. Our models
show that adenine could only be accommodated in T7
RNAP when O
6-meG was in the abnormal syn orientation
around its glycosidic bond; explaining the low adenine
misincorporation (Figure 7). No favorable models were
possible for the yRNAPII, explaining why adenine incor-
poration was not seen in the full-length transcripts.
CONCLUSION
The present work extends our understanding of lesion
processing by RNA polymerases and the possible atten-
dant sequelae of either TM or TCR. Our work and that of
others have provided studies of bulky lesions derived from
polycyclic aromatic carcinogens [reviewed in (60,71)] with
diverse shapes and stereochemical properties, as well as
the rigid 1,N
2-eG (26), the ﬂexible NI (27) and here the
smaller O
6-meG. From these investigations, we deduce
that the unique and speciﬁc hydrogen-bonding capabilities
of the lesion with diﬀerent incoming NTPs play an impor-
tant role in TM. For the speciﬁc case of O
6-meG, the
altered hydrogen-bond donor/acceptor properties
(Figure 1) allow for enhanced selectivity for uracil com-
pared to guanine in both T7 RNAP and hRNAPII. In
addition, lesion ﬂexibility has been pinpointed as an
important structural factor based on our studies of the
conformationally heterogenous NI lesion (27). Our results
show that for O
6-meG, the possible variation in the tor-
sion angle k, which governs the rotation about the O
6–C6
bond, and hence the placement of the bulky methyl group
in the polymerase active site is key. Both distal and prox-
imal conformations have been explicitly observed by
NMR (29–32) and X-ray crystallography (33,35,36). The
conformation of the methyl group is the determinant for
whether bypass or blockage occurs. Polymerase blockage
and the subsequent induction of TCR is connected to
steric hindrance by the lesion in the polymerase active
site. Blockage structures stem from a distal orientation
of the methyl group which places this sterically challen-
ging group in collision with the templating base. Our
results are consistent with earlier modeling studies sug-
gesting that multiple conformations of O
6-meG account
for the observed blockage and pyrimidine insertion during
in vitro replication (72). Thus, the subtle structural distinc-
tions between guanine and its O
6-methylated derivative
produce signiﬁcant consequences, not only as a muta-
tional damage during replication, but through its impact
on transcription. Further research is needed to discern the
impact of O
6-meG on the production of faulty proteins in
cells via TM and the potential impact of TCR on the
lesion’s clearance.
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